Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows ...

Mother diagnosed with terminal stomach cancer after mistaking symptom for side effect of diet - Mother-of-four Camilla ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

But a team of researchers led by Kishore Guda, associate professor at the Digestive Health Research Institute at the Case Western Reserve School of Medicine, found a special class of ribonucleic acid ...

GEMSTONE-303 is the first trial demonstrating a statistically significant survival benefit for addition of an anti-PD-L1 antibody to standard chemotherapy for advanced gastric and gastroesophageal ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...